GlassScriptPhysician profile
Saba Khokhar
NPI 1518133602
$1,845.58
in general payments reported to CMS, 2019-2025
14 companies · $33.95 in 2025
The $33.95 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,019 · 2020: $221 · 2021: $148 · 2022: $76.54 · 2023: $278 · 2024: $68.43 · 2025: $33.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $432.05 | 2019-2020 | |
| Viiv Healthcare Company | $362.31 | 2019-2024 | Cabenuva, Dovato |
| Gilead Sciences, INC. | $282.35 | 2019-2021 | |
| Melinta Therapeutics, LLC | $151.20 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $126.74 | 2019 | |
| Abbvie INC. | $114.67 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $102.17 | 2019-2023 | Pifeltro, Delstrigo, Dificid |
| Pfizer INC. | $72.46 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $68.41 | 2019 | |
| La Jolla Pharmaceutical Company | $36.97 | 2022-2023 | Xerava |
| Viatris Specialty LLC | $33.95 | 2025 | Yupelri |
| Insmed, INC. | $24.31 | 2020 | |
| Janssen Biotech, INC. | $23.40 | 2019 | |
| Smith+Nephew, INC. | $14.59 | 2023 | Regranex, Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Khokhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.